Complement 3d Receptors (Complement Receptor 2)

Subscribe to Selected New Research on Complement 3d Receptors

53 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor.

Also Known As:

Complement Receptor 2; Complement Receptors 2; Receptors, Complement 3d; CD 21 Antigens; CD21 Antigen; Complement 3d Receptor; Epstein-Barr Virus Receptor; Herpesvirus 4 Receptors, Human; Receptors, Epstein-Barr Virus; 2, Complement Receptor; 2, Complement Receptors; Antigen, CD21; Antigens, CD 21; Epstein Barr Virus Receptor; Epstein Barr Virus Receptors; Receptor 2, Complement; Receptor, Complement 3d; Receptor, Epstein-Barr Virus; Receptors 2, Complement; Receptors, Epstein Barr Virus; Virus Receptor, Epstein-Barr; Virus Receptors, Epstein-Barr; Antigens, CD21; C3d Receptors; CD21 Antigens; CR2 Receptors; Epstein-Barr Virus Receptors; Receptors, C3d; Receptors, CR2

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56712

Membrane Proteins: 4223

Cell Surface Receptors: 633

Virus Receptors: 41

Complement 3d Receptors: 53

Immunologic Receptors: 7

Complement Receptors: 599

Complement 3d Receptors: 53

Biological Factors: 872

Antigens: 93284

Surface Antigens: 3826

Differentiation Antigens: 867

CD Antigens: 29

Complement 3d Receptors: 53

Biological Markers: 18591

Differentiation Antigens: 867

CD Antigens: 29

Complement 3d Receptors: 53

Experts

1.	Boackle, Susan A: 2 articles (03/2007 - 01/2005)
2.	Ascherio, A: 1 article (08/2007)
3.	Yang, X: 1 article (08/2007)
4.	Munger, Kl: 1 article (08/2007)
5.	Simon, Kc: 1 article (08/2007)
6.	Cantor, Rita M: 1 article (03/2007)
7.	Shen, Nan: 1 article (03/2007)
8.	Hebert, Lee A: 1 article (03/2007)
9.	Hahn, Bevra H: 1 article (03/2007)
10.	Ulgiati, Daniela: 1 article (03/2007)

Related Diseases

1.	Neoplasms (Cancer) 11/01/1998 - "Immunohistochemical analysis revealed that both lung and liver tumors were negative for the Epstein-Barr virus receptor (CD21), and suggests that Epstein-Barr virus entry into the cells was not via this receptor but via an alternate mechanism such as cell fusion." 06/01/1994 - "Because the tumor cells were positive for the EB virus and CD21 antigen, EB virus seemed to have infected CD21-positive NK cells and transformed them" 10/01/1993 - "In normal and tumor cells of B lineage, CD38 was found to be also associated with surface Ig (sIg) and with the complement receptor 2 (CR2)/CD19 complex" 09/01/1992 - "Infusion of murine monoclonal antibodies specific for human B cell membrane antigens CD21, CD24, and CD23 was effective in 80% of animals, against two of the three cell lines preventing tumor development or inducing remission according to the time of treatment" 01/01/1998 - "Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections" Order ALL the reference details at left...
2.	Disease Progression 04/01/1997 - "Further studies are necessary to determine the possible association of higher expression of the CD21 antigen with disease progression and the aggressive character of the B-CLL." Order ALL the reference details at left...
3.	Infection 01/01/1997 - "The effect of RSV infection on the expression of B cell antigens CD21 and CD23, putative participants in Th2 responses, was investigated" 05/01/1990 - "Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells." 01/01/1992 - "While expression of complement receptor 2 (CR2) (CD21) on some CD4+ cell lines renders them more susceptible to infection by complement-treated human immunodeficiency virus (HIV), coexpression of CR2 and CD4 on peripheral blood lymphocytes has not, until recently, been observed" 07/25/1990 - "Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection." 05/01/1990 - "We investigated the possible role of the complement receptor 2 in enhancement of HIV-1 infection in CD4+ EBV-containing B cells by infecting such cells in the presence of sera from HIV sero-positive donors, with or without added human complement" Order ALL the reference details at left...
4.	Lymphoma (Lymphomas) 10/01/1995 - "Nasal natural killer (NK) cell lymphoma: report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells." 11/01/1983 - "The nodular or irregular tissue distribution patterns for Ig and C3d receptors found in histologically diffuse follicle derived lymphomas also suggest intratumoral variations in the marker expression, probably related to differentiation" 10/01/1982 - "Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: implications for the relationship between African and American Burkitt's lymphoma." 08/15/2005 - "Infection of human B lymphoma cells by Mycoplasma fermentans induces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21)." Order ALL the reference details at left...
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/06/2007 - "Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus." 01/01/2005 - "Role of complement receptor 2 in the pathogenesis of systemic lupus erythematosus." 11/01/1992 - "T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE)." 01/01/2002 - "Engagement of complement receptor 2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the increased responsiveness to antigen stimulation." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Complement System Proteins (Complement)
3.	Antigens
4.	Paraffin
5.	Membrane Proteins (Integral Membrane Proteins)
6.	Antibodies
7.	complement C3d,g
8.	CD7 Antigens
9.	Complementary DNA (cDNA)
10.	Complement 3b Receptors

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18530 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>